Your shopping cart is currently empty

GED-0507-34 Levo ((S)-3-(4-Aminophenyl)-2-methoxypropanoic acid), an orally available PPARγ modulator for amelioration of inflammation-driven intestinal fibrosis, decreased the expression of the pro-fibrotic genes Acta2, COL1a1, and Fn1, reduced the protein levels of α-SMA and collagen I-II, the main markers of fibrosis, as well as the major components of the TGFβ/Smad pathway, and decreased the expression of IL-13, CTGF, TGFB and ACTA1, and inhibited TGF-β-induced activation of fibroblasts and IECs cell lines.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $195 | In Stock | In Stock | |
| 5 mg | $483 | In Stock | In Stock | |
| 10 mg | $692 | In Stock | In Stock | |
| 25 mg | $1,080 | In Stock | In Stock | |
| 50 mg | $1,490 | In Stock | In Stock | |
| 100 mg | $1,970 | In Stock | In Stock | |
| 200 mg | $2,690 | - | In Stock |
| Description | GED-0507-34 Levo ((S)-3-(4-Aminophenyl)-2-methoxypropanoic acid), an orally available PPARγ modulator for amelioration of inflammation-driven intestinal fibrosis, decreased the expression of the pro-fibrotic genes Acta2, COL1a1, and Fn1, reduced the protein levels of α-SMA and collagen I-II, the main markers of fibrosis, as well as the major components of the TGFβ/Smad pathway, and decreased the expression of IL-13, CTGF, TGFB and ACTA1, and inhibited TGF-β-induced activation of fibroblasts and IECs cell lines. |
| In vitro | GED-0507-34 Levo was added to TGF-β–stimulated intestinal fibroblasts, epithelial cell lines, and primary fibroblasts from ulcerative colitis patients. Expression of α-SMA, Fn1, TGF-β, ACTA1, and epithelial markers was assessed. GED-0507-34 Levo inhibited TGF-β–induced fibrotic activation[1]. |
| In vivo | C57BL/6 mice (n = 110) were administered 2.5% DSS in drinking water (3 cycles over 6 weeks) to induce intestinal fibrosis, and treated daily with GED-0507-34 Levo (30 mg/kg/d; oral). Fibrosis severity was evaluated via macroscopic/histological scores and fibrosis marker expression. GED-0507-34 Levo treatment alleviated intestinal fibrosis[1]. |
| Synonyms | Y4H78S56YZ, (S)-3-(4-Aminophenyl)-2-methoxypropanoicacid, (S)-3-(4-Aminophenyl)-2-methoxypropanoic acid |
| Molecular Weight | 195.22 |
| Formula | C10H13NO3 |
| Cas No. | 921195-93-9 |
| Smiles | C([C@@H](C(O)=O)OC)C1=CC=C(N)C=C1 |
| Storage | keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.